Zymeworks shifts focus to ZW251 for liver cancer, delaying ZW220. Q4 revenue and earnings missed estimates. GSK milestone ...

The FDA has approved Neffy, a needle-free nasal spray, for children aged 4 and up, providing fast and effective treatment for severe allergic reactions and anaphylaxis.

The Food and Drug Administration (FDA) has approved neffy ® (epinephrine nasal spray) 1mg for the emergency treatment of type 1 allergic reactions, including anaphylaxis, in pediatric patients aged 4 ...

The FDA is expected to decide on treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine.

ARS Pharmaceuticals’ (Nasdaq: SPRY) shares closed up 3.4% at $10.87 yesterday, after the company announced that the US Food ...

Over 31 million Americans borrowed a collective $74 billion to pay for healthcare last year, a West Health-Gallup survey ...

Neffy 1 mg is the “first significant innovation” for epinephrine delivery in small children aged 4 years and up in over 35 ...

The U.S. Food and Drug Administration has expanded its indication of ALK's Odactra, a house dust mite allergen tablet, for ...

"We are currently engaging with market participants," a spokesperson for South Africa's Competition Commission told Reuters, declining to provide details. USAID cuts put tuberculosis response in peril ...

HOLDINGS announce that its wholly owned subsidiary, Scienture has entered into a definitive agreement with SUMMIT BIOSCIENCES, ...

SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through ...

The approval is supported by data from clinical trials, including pharmacodynamic and pharmacokinetic responses in adults and ...